title: Prognostic variables in greek patients with stage II breast cancer: a Hellenic Cooperative Oncology Group study.
abstract: The independent effects of several patient, tumor and treatment-related prognostic factors on relapse-free survival (RFS) and overall survival (OS) were assessed by Cox multivariate regression analysis in 988 Greek patients with stage II breast cancer. At a median follow-up time of 83 (range 3.3-131+) months and after the evaluation of all patients together, the number of positive axillary nodes (p < 0.0001), tumor size (p = 0.0024) and tumor grade (p = 0.0008) were identified as significant prognostic factors for RFS. Also, the number of positive nodes (p < 0.0001), tumor size (p = 0.0002) and ER status (p = 0.0001) were found to be significant for OS. These short-term prognostic variables are similar to those reported for this group of patients in other European countries and in the USA.
authors.affiliation: AHEPA Hospital, Aristotle University of Thessaloniki, Greece.
authors.forename: G
authors.initials: G
authors.lastname: Fountzilas
authors.forename: S
authors.initials: S
authors.lastname: Vasilaros
authors.forename: D
authors.initials: D
authors.lastname: Koukouras
authors.forename: N
authors.initials: N
authors.lastname: Malamos
authors.forename: D
authors.initials: D
authors.lastname: Pectasides
authors.forename: A
authors.initials: A
authors.lastname: Adamou
authors.forename: E
authors.initials: E
authors.lastname: Nenopoulou
authors.forename: K
authors.initials: K
authors.lastname: Kiriakou
authors.forename: I
authors.initials: I
authors.lastname: Zouvani
authors.forename: K
authors.initials: K
authors.lastname: Katsohis
authors.forename: A
authors.initials: A
authors.lastname: Kappas
authors.forename: C
authors.initials: C
authors.lastname: Skopa
authors.forename: C
authors.initials: C
authors.lastname: Semoglou
authors.forename: E
authors.initials: E
authors.lastname: Fahantidis
authors.forename: C
authors.initials: C
authors.lastname: Konstantaras
authors.forename: E
authors.initials: E
authors.lastname: Vasilaki
authors.forename: T
authors.initials: T
authors.lastname: Economopoulos
authors.forename: H
authors.initials: H
authors.lastname: Bacoyiannis
authors.forename: D
authors.initials: D
authors.lastname: Bafaloukos
authors.forename: E
authors.initials: E
authors.lastname: Razi
authors.forename: A
authors.initials: A
authors.lastname: Polichronis
authors.forename: G
authors.initials: G
authors.lastname: Androulakis
authors.forename: T
authors.initials: T
authors.lastname: Papaioannou
authors.forename: N
authors.initials: N
authors.lastname: Pavlidis
authors.forename: P
authors.initials: P
authors.lastname: Kosmidis
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005060:Europe; D005260:Female; D006115:Greece; D006801:Humans; D008207:Lymphatic Metastasis; D008499:Medical Records; D008593:Menopause; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis; D012008:Recurrence; D012044:Regression Analysis; D012189:Retrospective Studies; D015996:Survival Rate; D013629:Tamoxifen / Q000627:therapeutic use; D014481:United States
chemical_list: D011960:Receptors, Estrogen; D013629:Tamoxifen